-
In patients with stable coronary artery disease (CAD), medical therapy is the mainstay of treatment. Percutaneous coronary intervention (PCI) guided by angiographic stenosis is more effective than medical therapy at reducing angina, but does not change the rate of death or myocardial infarction (MI).
-
The risk of interrupting prophylactic warfarin for stroke prevention in atrial fibrillation (AF) patients is unclear. Thus, these investigators from Denmark evaluated their national health registry and found 102,591 patients > age 30 with a first-time hospitalization for AF between 1997 and 2008.
-
Side effects of statins; effects of cannabis use; antihypertensives and lip cancer; and FDA actions.
-
-
Patients who present with acute myocardial infarction (MI) complicated by cardiogenic shock represent a group at high risk for early mortality.
-
More than 200,000 Riata family implantable cardioverter-defibrillator (ICD) leads from St. Jude Medical were implanted worldwide. Recently, the FDA issued a Class I recall on this lead because of the appearance of defects in the lead insulation that may lead to externalization of the conductor wires.
-
This paper reports registry data from a large, single-center patient cohort with myotonic dystrophy type 1 (DM1). Between January 2000 and December 2009, 914 adult patients were included in the DM1 Heart Registry at the authors' institution.
-
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Study compared two doses of dabigatran, a direct thrombin inhibitor, with warfarin for the prevention of stroke and systemic emboli in patients with nonvalvular atrial fibrillation (AF).
-
Some patients who experience stroke or transient ischemic attack (TIA) of unknown cause (i.e., cryptogenic) are subsequently found to have a patent foramen ovale (PFO).
